Loading...
•
Dec 31, 2024
Protalix Q4 2024 Earnings Report
Protalix reported increased product sales and a strong balance sheet after full debt repayment.
Key Takeaways
Protalix BioTherapeutics delivered a solid Q4-24, driven by strong product sales to Chiesi, Pfizer, and Brazil. The company repaid all outstanding debt and strengthened its balance sheet. Net income improved despite lower license and R&D service revenue.
Record sales revenue from goods, driven by Chiesi, Pfizer, and Brazil.
Full repayment of outstanding debt, eliminating interest expenses.
Decrease in license and R&D services revenue due to prior-year milestone payments.
Continued progress in clinical pipeline, including PRX-115 for uncontrolled gout.
Protalix
Protalix
Protalix Revenue by Segment
Protalix Revenue by Geographic Location
Revenue by Segment
Selling Goods Revenue
CapyFin.comRevenue by Geographic Location
Pfizer Revenue
CapyFin.comFiocruz (Brazil) Revenue
CapyFin.com Forward Guidance
Protalix expects continued growth in product sales and progress in its clinical pipeline but remains cautious about revenue from license agreements.
Positive Outlook
- Steady increase in product sales, particularly to Chiesi and Brazil.
- Debt-free status enhances financial stability.
- Continued development of PRX-115 with potential Phase II trial in 2025.
- Potential for additional regulatory approvals and expanded indications.
- Improved operational efficiency with reduced costs.
Challenges Ahead
- Declining revenue from license and R&D services.
- Potential market competition affecting future sales.
- Regulatory risks associated with product approvals.
- Macroeconomic uncertainties impacting healthcare budgets.
- Fluctuating foreign exchange rates affecting international sales.